VitaSpring is a development-stage biomedical company focusing on mesenchymal stem cells derived from human placental tissue and exosomes derived from those cells. The company identifies its core technology as X.msc and targets potential applications in regenerative medicine, wound healing, skincare, and anti-aging. VitaSpring currently generates no revenue, offers no products, and maintains no active research and development programs. For FY25 and FY26, the company incurred no R&D expenses. VitaSpring operates with one executive and has no full-time employees. Existing scientific findings rely on internal data from affiliated partners in Taiwan that lacks independent validation or regulatory review. The company has not yet submitted FDA applications or initiated clinical programs. VitaSpring plans to utilize a B2B business model to serve institutional and clinical customers through contract manufacturing, product sales, licensing, and consulting. These future operations depend entirely on securing financing, which the company has not yet obtained. VitaSpring holds no issued patents or registered trademarks and relies on trade secrets and technical know-how. Management projects that hospital implementation of its technology could begin within five years, though this timeline is contingent on future financing and regulatory progress.